- Home
- BGI vs BCTX Comparison
BGI vs BCTX Comparison
Compare BGI & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGI | BCTX |
|---|---|---|
| Founded | 1879 | 2014 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 18.5M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | BGI | BCTX |
|---|---|---|
| Price | $1.03 | $9.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 28.0K | ★ 57.6K |
| Earning Date | 12-05-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $136,846,182.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $0.56 | $6.00 |
| 52 Week High | $2.03 | $106.50 |
Technical Indicators
Market Signals| Indicator | BGI | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 42.83 |
| Support Level | $1.00 | $11.38 |
| Resistance Level | $1.09 | $13.09 |
| Average True Range (ATR) | 0.05 | 1.14 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 20.05 | 10.47 |
Price Performance
Historical ComparisonAbout BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.